In June 2024, Daewoong Pharmaceutical revealed its plans to collaborate with Indonesia’s Bogor Agricultural University (IPB), highly regarded for its veterinary research expertise, to establish a specialized primate research institute in the Southeast Asian country. This partnership, which aims to advance preclinical research and facilitate new drug development, represents a major development in the pharmaceutical and biotechnology fields in Indonesia.
The collaboration, formalized through a Memorandum of Understanding (MOU), will involve setting up the research institute at IPB and will focus on commercializing pharmaceuticals and medical devices through primate studies. It will also contribute to the development of skilled veterinarians. The research will be conducted in association with PSSP, an IPB-linked primate research center with over three decades of experience in primate research.
The new institute is expected to improve the reliability of preclinical studies by examining primates with diseases similar to human conditions. This is crucial for evaluating the safety and effectiveness of new drugs before human trials.
According to IPB Vice President Iskandar, the collaboration with Daewoong Pharmaceutical is anticipated to bring significant value and further enhance talent development due to IPB’s leading capabilities in primate research. The new collaboration with IPB is expected to drive advancements in preclinical research and foster growth in the region’s pharmaceutical and biotechnology industries.
(Source: Business Korea)
